ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

Manchester, United Kingdom 11-13 March 2020

CO-CHAIRS:

Fiona Blackhall, United Kingdom Enriqueta Felip, Spain Raffaele Califano, United Kingdom

SPEAKERS:

Mo Al Aloul, United Kingdom
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Anne-Marie C. Dingemans, Netherlands
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Martin Früh, Switzerland
Pilar Garrido López, Spain
Karin Jordan, Germany
Keith M. Kerr, United Kingdom

Rohit Kochhar, United Kingdom Cécile Le Péchoux, France Catherine McBain, United Kingdom Luis Paz-Ares, Spain David Planchard, France Martin Reck, Germany Suresh Senan, Netherlands Yvonne Summers, United Kingdom Paul Taylor, United Kingdom Fiona Thistlethwaite, United Kingdom Paul E. Van Schil, Belgium Giulia Veronesi, Italy David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

Wednesday, 11 March 2020

08:15-09:15 60'	Registration	
09:15-10:55 100'	SESSION 1 Screening and diagnostics for lung cancer	Chairs: Enriqueta Felip, ES Raffaele Califano, UK
40'	Lung cancer screening	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
10:55-11:20	Coffee break	

11:20-12:20 60'	SESSION 1 - cont. Screening and diagnostics for lung cancer	Fiona Blackhall, UK Raffaele Califano, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Medical thoracoscopy in the management of thoracic malignancies	Mo Al Aloul, UK
12:20-13:40	Lunch	
13:40-16:00 120'	SESSION 2 Radical treatment of early stage NSCLC	Chairs: Giulia Veronesi, IT Cécile Le Péchoux, FR
30'	Surgery for early stage NSCLC	Giulia Veronesi, IT
30'	Stereotactic ablative RT for early stage NSCLC	Suresh Senan, NL
14:40-15:00	Coffee break	
30'	Adjuvant radiotherapy for completely resected early stage NSCLC	Cécile Le Péchoux, FR
30'	Adjuvant chemotherapy for resected early stage NSCLC	Paul Taylor, UK
16:00-16:10 10'	Close of day 1	Chairs: Fiona Blackhall, UK Raffaele Califano, UK

Chairs:

Thursday, 12 March 2020

09:05-10:35 90'	SESSION 3 - cont. Advanced NSCLC	Chairs: Fiona Blackhall, UK Martin Reck, DE
30'	1st line chemotherapy for advanced NSCLC	David Planchard, FR
30'	1st line Immune-checkpoint blockade for NSCLC	Luis Paz-Ares, ES
30'	2 nd line treatment for advanced NSCLC	Martin Reck, DE
10:35-12:55 120'	SESSION 3 - cont. Advanced NSCLC	Chairs: Fiona Blackhall, UK Yvonne Summers, UK
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
11:05-11:25	Coffee break	
30'	Treatment of ALK/ROS1 positive advanced NSCLC	Fiona Blackhall, UK
30'	Maintenance treatment for advanced NSCLC	Yvonne Summers, UK
30'	Beyond ALK /ROS1 and EGFR: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
12:55-14:00	Lunch	
14:00-15:00 60'	SESSION 4 Palliative treatment of lung cancer and mesothelioma	Chairs: Enriqueta Felip, ES Paul Baas, NL
30'	Systemic treatment of mesothelioma	Paul Baas, NL
30'	Treatment of oligometastatic NSCLC	Anne-Marie C. Dingemans, NL
15:00-15:30	Coffee break	

15:30-16:30 60'	SESSION 4 - cont. Palliative treatment of lung cancer and mesothelioma	Chairs: Raffaele Califano, UK Tora S. Solheim, NO
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Catherine McBain, UK
30'	Supportive and palliative care in lung cancer	Karin Jordan, DE
16:30-16:35 5'	Close of day 2	Chairs: Fiona Blackhall, UK Raffaele Califano, UK
	Close of day 2 Welcome drink	Fiona Blackhall, UK

Friday, 13 March 2020

09:10-10:40 90'	SESSION 5 Locally advanced NSCLC	Chairs: Fiona Blackhall, UK Paul E. Van Schil, BE
30'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
30'	Combined modality treatment for NSCLC with N2 disease	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10:40-11:00	Coffee break	
11:00-12:00 60'	SESSION 5 - cont. Locally advanced NSCLC	Chairs: Corinne Faivre-Finn, UK Paul E. Van Schil, BE
60'	Participants clinical case discussion (3x20')	Faculty

Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / interactive panel discussion

12:00-13:00	Lunch	
13:00-15:00 120'	SESSION 6 SCLC	Chairs: Corinne Faivre-Finn, UK Enriqueta Felip, ES
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
30'	Chemotherapy for extensive stage SCLC	Martin Früh, CH
30'	Immune checkpoint blockade for SCLC	Pilar Garrido López, ES
30'	Targeted agents in SCLC	Enriqueta Felip, ES
15:00-15:15	Coffee break	
15:15-16:15 60'	SESSION 6 - cont. SCLC	Chairs: Enriqueta Felip, ES Raffaele Califano, UK
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Neil Bayman, UK
30'	Cellular immunotherapy	Fiona Thistlethwaite, UK
16:15-16:20 5'	Conclusion and farewell	Raffaele Califano, UK